{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:53:25Z","timestamp":1785916405192,"version":"3.56.0"},"reference-count":28,"publisher":"American Society of Hematology","issue":"15","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,13]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising immunotherapeutic strategy for eradicating human cancers. Their therapeutic success and durability of clinical responses hinges, in large part, on their functional capacity, including the ability of these engineered cells to simultaneously expand and persist after infusion into patients. CD19 CAR T-cell polyfunctionality, assessing the simultaneous functions of cytokine production, proliferation, and cytotoxicity has been reported to correlate with clinical outcomes. Assay optimization is potentially limited by the heterogeneous nature of CAR T-cell infusion products and target specificity. We optimized a single-cell platform for polyfunctionality using CAR T-cell products manufactured from healthy donors, engineered against a novel target, B-cell\u2013activating factor receptor\u00a0(BAFF-R) and validated the protocol using CD19 CAR T cells. We observed distinct qualitative differences between BAFF-R and CD19 CAR T cells relative to the proportions of stimulatory vs effector cytokines, based on target antigen density, and, generally, CD19 CAR T cells exhibited lower indices of polyfunctionality. Finally, we applied our assay to the autologous BAFF-R CAR T-cell product generated from the first patient with non-Hodgkin lymphoma treated in an ongoing clinical trial who had progressed after prior CD19 CAR T-cell therapy. We observed robust indicators of polyfunctionality, which correlated with successful CAR T-cell expansion after infusion and achievement of durable complete remission ongoing after 18\u00a0months. The precise identification of factors determining the role of BAFF-R CAR T-cell fitness in toxicity and clinical outcome will require the application of this robust assay in the analysis of additional treated patients. This trial was registered at www.ClinicalTrials.gov as #NCT05370430.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013195","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T20:02:24Z","timestamp":1718654544000},"page":"4066-4076","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Analysis of polyfunctionality for enhanced BAFF-R CAR T-cell therapy for hematologic malignancies"],"prefix":"10.1182","volume":"8","author":[{"given":"Zhengyuan","family":"Dong","sequence":"first","affiliation":[{"name":"1Toni Stephenson Lymphoma Center, Beckman Research Institute, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1464-5494","authenticated-orcid":false,"given":"L. Elizabeth","family":"Budde","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Oh","sequence":"additional","affiliation":[{"name":"1Toni Stephenson Lymphoma Center, Beckman Research Institute, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szymon","family":"Szymura","sequence":"additional","affiliation":[{"name":"1Toni Stephenson Lymphoma Center, Beckman Research Institute, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0791-9717","authenticated-orcid":false,"given":"Aaron","family":"Anderson","sequence":"additional","affiliation":[{"name":"1Toni Stephenson Lymphoma Center, Beckman Research Institute, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Del Real","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soung-chul","family":"Cha","sequence":"additional","affiliation":[{"name":"1Toni Stephenson Lymphoma Center, Beckman Research Institute, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry W.","family":"Kwak","sequence":"additional","affiliation":[{"name":"1Toni Stephenson Lymphoma Center, Beckman Research Institute, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Wang","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"issue":"8","key":"2024081312510072300_bib1","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"2024081312510072300_bib2","article-title":"","author":"Howlader","year":"2014","journal-title":"SEER Cancer Statistics Review 1975-2012"},{"issue":"1","key":"2024081312510072300_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40425-017-0293-7","article-title":"Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response","volume":"5","author":"Xue","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"511","key":"2024081312510072300_bib4","doi-asserted-by":"crossref","first-page":"eaaw9414","DOI":"10.1126\/scitranslmed.aaw9414","article-title":"CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies","volume":"11","author":"Qin","year":"2019","journal-title":"Sci Transl Med"},{"issue":"6","key":"2024081312510072300_bib5","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1182\/bloodadvances.2022008560","article-title":"Generation of a humanized afucosylated BAFF-R antibody with broad activity against human B-cell malignancies","volume":"7","author":"Dong","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"2024081312510072300_bib6","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1078-0432.CCR-22-2038","article-title":"Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapsed\/refractory ALL","volume":"29","author":"Aldoss","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2024081312510072300_bib7","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","article-title":"CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in\u00a0vivo persistence and antitumor efficacy of adoptively transferred T cells","volume":"66","author":"Kowolik","year":"2006","journal-title":"Cancer Res"},{"issue":"5","key":"2024081312510072300_bib8","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","article-title":"A\u00a0transgene-encoded cell surface polypeptide for selection, in\u00a0vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2024081312510072300_bib9","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1007\/s00262-020-02614-8","article-title":"Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions","volume":"69","author":"Dong","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2024081312510072300_bib10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1158\/2326-6066.CIR-20-0236","article-title":"The cerebroventricular environment modifies CAR T cells for potent activity against both central nervous system and systemic lymphoma","volume":"9","author":"Wang","year":"2021","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"2024081312510072300_bib11","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/sj.gt.3302440","article-title":"A\u00a0lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice","volume":"12","author":"Charrier","year":"2005","journal-title":"Gene Ther"},{"issue":"8","key":"2024081312510072300_bib12","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2018-01-828343","article-title":"Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2024081312510072300_bib13","doi-asserted-by":"crossref","first-page":"e42403","DOI":"10.1371\/journal.pone.0042403","article-title":"Evaluating cellular polyfunctionality with a novel polyfunctionality index","volume":"7","author":"Larsen","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"2024081312510072300_bib14","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1182\/bloodadvances.2022008490","article-title":"Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells","volume":"7","author":"Michelozzi","year":"2023","journal-title":"Blood Adv"},{"issue":"21","key":"2024081312510072300_bib15","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1182\/blood.V122.21.4185.4185","article-title":"B-1239, a novel anti-BAFF-R afucosylated human antibody, promotes potent natural killer cell- mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia cells in- vitro and depletion of circulating leukemic CLL B cells in-vivo","volume":"122","author":"McWilliams","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2024081312510072300_bib16","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1038\/s41467-022-30860-0","article-title":"A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun"},{"issue":"11","key":"2024081312510072300_bib17","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1158\/2326-6066.CIR-22-0115","article-title":"Secreted Fas decoys enhance the antitumor activity of engineered and bystander T cells in Fas ligand-expressing solid tumors","volume":"10","author":"Bajgain","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"2024081312510072300_bib18","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.jcyt.2022.03.011","article-title":"Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies","volume":"24","author":"Zurko","year":"2022","journal-title":"Cytotherapy"},{"issue":"4","key":"2024081312510072300_bib19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri1052","article-title":"Cytokine control of memory T-cell development and survival","volume":"3","author":"Schluns","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2024081312510072300_bib20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/jir.2017.0101","article-title":"IL-2 and beyond in cancer immunotherapy","volume":"38","author":"Wrangle","year":"2018","journal-title":"J\u00a0Interferon Cytokine Res"},{"issue":"18","key":"2024081312510072300_bib21","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2024081312510072300_bib22","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1128\/JVI.06797-11","article-title":"CD4\u00a0T cells promote CD8\u00a0T cell immunity at the priming and effector site during viral encephalitis","volume":"86","author":"Phares","year":"2012","journal-title":"J\u00a0Virol"},{"issue":"6925","key":"2024081312510072300_bib23","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nature01441","article-title":"CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes","volume":"421","author":"Janssen","year":"2003","journal-title":"Nature"},{"issue":"12","key":"2024081312510072300_bib24","doi-asserted-by":"crossref","first-page":"8243","DOI":"10.4049\/jimmunol.179.12.8243","article-title":"CD4\u00a0T cells are required for CD8\u00a0T cell survival during both primary and memory recall responses","volume":"179","author":"Novy","year":"2007","journal-title":"J\u00a0Immunol"},{"issue":"5617","key":"2024081312510072300_bib25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1126\/science.1083317","article-title":"Defective CD8\u00a0T cell memory following acute infection without CD4\u00a0T cell help","volume":"300","author":"Sun","year":"2003","journal-title":"Science"},{"issue":"5","key":"2024081312510072300_bib26","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov"},{"issue":"9","key":"2024081312510072300_bib27","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","article-title":"Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase","volume":"25","author":"Walker","year":"2017","journal-title":"Mol Ther"},{"issue":"3","key":"2024081312510072300_bib28","doi-asserted-by":"crossref","first-page":"911","DOI":"10.4049\/jimmunol.1402346","article-title":"Target antigen density governs the efficacy of anti-CD20-CD28-CD3 \u03b6 chimeric antigen receptor-modified effector CD8+ T cells","volume":"194","author":"Watanabe","year":"2015","journal-title":"J\u00a0Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/15\/4066\/2238149\/blooda_adv-2024-013195-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/15\/4066\/2238149\/blooda_adv-2024-013195-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T12:51:23Z","timestamp":1723553483000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/15\/4066\/516562\/Analysis-of-polyfunctionality-for-enhanced-BAFF-R"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":28,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,8,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013195","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]}}}